H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $70.00 price target on Compass Pathways (NASDAQ: CMPS).

The analyst commented: "On March 24, COMPASS Pathways, an HCW 2026 top pick, reported 4Q25 and 2025 results highlighted by a clear regulatory path to a potential rolling new drug application (NDA) in 4Q26 and framework for a scalable commercial model leveraging the existing interventional psychiatry infrastructure. Additionally, in our view, the $350 million capital raised in 1Q26 removes any financing overhang and extends runway into 2028, fully funding COMPASS through NDA submission, potential approval, and initial launch, which we view as de-risking as COMPASS transitions to a commercial stage company. Furthermore, the FDA’s acceptance of the investigational new drug (IND) application for COMP360 in post-traumatic stress disorder (PTSD) advances the second major indication into registrational development and provides a potential expansion opportunity beyond TRD. In our view, these developments reinforce our core thesis that clinical risk is largely retired, and the investment debate has shifted to regulatory sequencing, commercial readiness, and durability-driven economics. We reiterate our Buy rating and $70 price target."

For an analyst ratings summary and ratings history on Compass Pathways click here. For more ratings news on Compass Pathways click here.

Shares of Compass Pathways closed at $5.62 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Some Glazer family members said to consider selling Manchester United plc (MANU) stake - Bloomberg
• Greenway Technologies board member Raymond Wright resigns